Search for 'Provider:Annals of oncology: official journal of the European Society for Medical Oncology, and au:Castellano, Daniel'

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015 . 26(9):1987-93. , Formato Vancouver: Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015 Sep; 26(9):1987-93.

Place Hold on Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).

Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).

By Castellano, Daniel. Annals of oncology : official journal of the European Society for Medical Oncology, 2014 . 25(11):2173-8. , Formato Vancouver: Aparicio J, Maroto P, García Del Muro X, Sánchez Muñoz A, Gumà J, Margelí M et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol. 2014 Nov;25(11):2173-8.

Place Hold on Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG).